期刊文献+

细胞色素P4503A4与P4503A5及多药耐药基因多态性对氨氯地平降压疗效影响研究 被引量:7

Effect of cytochrome P3A4,CYP3A5 and multidrug resistant gene polymorphism on antihypertensive effect of amlodipine
原文传递
导出
摘要 目的探讨细胞色素P450(CYP)3A4*1G、CYP3A5*3及多药耐药(MDR1)C1236T、MDR1 G2677T/A和MDR1 C3435T基因多态性对氨氯地平降压疗效的影响。方法纳入159名原发性高血压患者,予氨氯地平5 mg·d-1干预4周,检测相关基因型,分析不同个体CYP3A4、3A5及MDR1相关基因型分布特征,考察不同单核苷酸多态性(SNP)及MDR1单倍体对氨氯地平降压疗效的影响。结果 CYP3A4*1G*1G基因型舒张压(DBP)下降幅度显著低于CYP3A4*1G*1和CYP3A4*1*1(P<0.05);CYP3A5*3*3基因型DBP下降幅度显著高于CYP3A5*1*3和CYP3A5*1*1(P<0.05);MDR1 C1236T CC、MDR1 G2677T/A AA基因型收缩压(SBP)下降幅度显著高于其他基因型(P<0.05);MDR1 C3435T各基因型治疗前后SBP、DBP下降幅度差异均无统计学意义(P>0.05)。携带MDR1 C3435T CC、MDR1 C3435T CT基因型的患者的DBP下降幅度,女性显著高于男性(P<0.05)。对MDR1单倍体分析,各组单倍体治疗前后SBP、DBP下降幅度差异均无统计学意义(P>0.05)。结论CYP3A5*3、CYP3A4*1G基因多态性可影响氨氯地平降压疗效,MDR1各单倍体未发现与氨氯地平降压疗效相关。 Objective To analyse the association of cytochrome P450 (CYP) 3A4*1G,CYP3A5*3,multidrug resistant gene (MDR1) C1236T,MDR1 G2677T/A and MDR1 C3435T gene polymorphisms on antihypertensive effect of amlodipine.Methods A total of 159 patients were screened who were assigned to receive amlodipine 5 mg · d ^-1 for 4 weeks.Antihypertensive effects were analyzed according to genotype and haploid.Results Patients with CYP3A4*1G*1G genotype had lower diastolic blood pressure ( DBP) reduction than CYP3A4*1G*1 and CYP3A4*1*1 genotype(P〈0.05).Patients with CYP3A5*3*3 gen-otype had higher DBP reduction than CYP3A5*1*3 and CYP3A5*1*1 genotype ( P 〈0.05 ).Patients with MDR1 C1236T CC, MDR1 G2677 T/A AA genotype had higher systolic blood pressure ( SBP ) re-duction than those other genotypes ( P 〈0.05 ).Female patients with MDR1 C3435T CC, MDR1 C3435T CT genotypes had higher DBP reduc-tion than male patients carried the same genotype(P〈0.05).No significant relationship was found between haploid composed by MDR1(P〈0.05).Conclusion CYP3A5*3 and CYP3A4*1 gene polymorphisms can affect antihypertensive effect to amlodipine.Female patients with MDR1 C3435 T CC and MDR1 C3435T CT genotypes had higher DBP reduction than male patients carried the same genotype, haploid com-posed by MDR1 was not found related to amlodipine antihypertensive effect.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第11期983-987,共5页 The Chinese Journal of Clinical Pharmacology
基金 广东省科技计划基金资助项目(2011B061200025)
关键词 原发性高血压 氨氯地平 基因多态性 细胞色素P4503A4 3A5 多药耐药基因 hypertension amlodipine polymorphism cytochrome P4503 A4,3 A5 multidrug resistant gene
  • 相关文献

参考文献11

  • 1Kwon HM, Shin JW, Lim JS, et al. Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients l a prospective, randomized, double - blind, comparative parallel study [J]. Clin Ther, 2013, 35: 1975 - 1982.
  • 2Du J, Yu L, Wang L, et al. Differences in CYP3A41G gcnotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations [J]. Clin Chim Acta, 2007, 383:172- 174.
  • 3Miao LY, Huan CR, Hou JQ, et al. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentra- tion and dose requirements in Chinese renal transplant recipients [J]. Biopharm Drug Dispos, 2008, 29:1 -51.
  • 4Gao Y, Zhang LR, Fu Q. CYP3A4 * 1G polymorphism is associat- ed with lipid - lowering efficacy of atorvastatin but not of simvastatin[J]. Eur J Clin Pharm, 2008,64: 877 -8821.
  • 5Bhatnagar V, Gareia EP, O'Connor DT, et al. CYP3A4 andCYP3A5 polymorphisms and blood pressure response to amlodipine among African - American men and women with early hypertensive renal disease [J]. Am J Nephrol, 2010, 31: 95-103.
  • 6Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liv- er microsomes and roles of CYP3A4/5 in the dihydropyridine dehy- drogenation [ J ]. Drug Metab Dispos, 2014,42 : 245 - 249.
  • 7Lee SJ, Bell DA, Coulter SJ, et al. Recombinant CYP3A4 * 17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4 * 17 allele may occur on the same chromosome as CYP3A5 *3, respresenting a new putative defective CYP3A haplotype [J]. J Pharmacol Exp Ther, 2005, 313:302-309.
  • 8Kirn KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5genotype on the single- dose simvastatin pharmacokinetics in healthy subject [ J]. J Clin Pharmacol, 2007,47:87 -93.
  • 9文娟,黄志军,袁洪,邢晓为,赵秋平,席兰艳.肾移植后高血压人群中CYP3A4*1G、CYP3A5*3和MDR1 C3435T基因多态性对氨氯地平降压疗效的影响[J].中国动脉硬化杂志,2011,19(1):55-60. 被引量:19
  • 10Kim KA, Park PW, Park JY. Effect of cytoehrome P450 3A5 * 3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects [ J ]. Chirality, 2009,21:485 - 491.

二级参考文献6

共引文献18

同被引文献62

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部